Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon Will Likely Require Refinancing Before Re-Submitting Provenge BLA

This article was originally published in The Pink Sheet Daily

Executive Summary

Company believes it has the necessary cash to extend through timing of interim results of IMPACT study evaluating the cancer vaccine in 2008.

You may also be interested in...



Provenge Review In 2008 Hinges On IMPACT Interim Analysis

FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.

Provenge Review In 2008 Hinges On IMPACT Interim Analysis

FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.

Dendreon’s Therapeutic Vaccine Provenge Gets “Complete Response” From FDA

FDA is requesting additional clinical data to support the efficacy of Dendreon’s BLA.

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel